deltatrials
Unknown OBSERVATIONAL NCT00173771

Development of a Comprehensive ADL Scale for Stroke Patients

Sponsor: National Science and Technology Council, Taiwan

Updated 7 times since 2017 Last updated: Sep 13, 2005 Started: Aug 31, 2004 Completion: May 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00173771, this observational or N/A phase trial focuses on Cerebrovascular Accidents and remains ongoing. Sponsored by National Science and Technology Council, Taiwan, it has been updated 7 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

our research team will develop a new CADL scale for stroke patients over the next three years. In the first year (an ongoing project: NSC 93-2314-B-002-284), we had established a CADL item bank of 50 items. The investigators will administer the 50 items on 300 patients with stroke living in the community. Then we will select 10 to 15 items from the item bank for the CADL scale based on the International Classification of Functioning, Disability and Health (ICF), the opinions of an expert panel, and Rasch analysis. It is anticipated that the CADL scale will have unidimensionality, an interval level of measurement, soundly psychometric characteristics, a reduced number of items, and ease of administration. In the second and third years, we will compare the psychometric properties of the CADL scale and the combined BI and FAI scale. The psychometric properties investigated will include reliability (e.g. inter-rater reliability, intra-rater reliability, and internal consistency), validity (e.g. concurrent validity, convergent validity, predictive validity and discriminant validity), and responsiveness. A total of 150 patients will be recruited. Both the CADL scale and the combined BI and FAI scale will be used on patients from the initial stage (within one month) to six months...

our research team will develop a new CADL scale for stroke patients over the next three years.

In the first year (an ongoing project: NSC 93-2314-B-002-284), we had established a CADL item bank of 50 items. The investigators will administer the 50 items on 300 patients with stroke living in the community. Then we will select 10 to 15 items from the item bank for the CADL scale based on the International Classification of Functioning, Disability and Health (ICF), the opinions of an expert panel, and Rasch analysis. It is anticipated that the CADL scale will have unidimensionality, an interval level of measurement, soundly psychometric characteristics, a reduced number of items, and ease of administration.

In the second and third years, we will compare the psychometric properties of the CADL scale and the combined BI and FAI scale. The psychometric properties investigated will include reliability (e.g. inter-rater reliability, intra-rater reliability, and internal consistency), validity (e.g. concurrent validity, convergent validity, predictive validity and discriminant validity), and responsiveness. A total of 150 patients will be recruited. Both the CADL scale and the combined BI and FAI scale will be used on patients from the initial stage (within one month) to six months after hospital discharge. The results will be useful for researchers and clinicians to determine whether the CADL scale is better than the combined BI and FAI scale in stroke patients.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotUnknown Status~Apr 2018 – ~Jan 2021 · 33 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotUnknown~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshotUnknown~Sep 2025 – present · 7 months · monthly snapshotUnknown

Change History

7 versions recorded
  1. Sep 2025 — Present [monthly]

    Unknown

  2. Jun 2025 — Sep 2025 [monthly]

    Unknown

  3. Sep 2024 — Jun 2025 [monthly]

    Unknown

  4. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown StatusUnknown

  5. Jan 2021 — Jul 2024 [monthly]

    Unknown Status

Show 2 earlier versions
  1. Apr 2018 — Jan 2021 [monthly]

    Unknown Status

    Phase: NANone

  2. Jan 2017 — Apr 2018 [monthly]

    Unknown Status NA

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Science and Technology Council, Taiwan
  • National Taiwan University Hospital
Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations